株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

トゥレット症候群治療薬の世界市場:2019年~2023年

Tourette's Syndrome Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 910224
出版日 ページ情報 英文 145 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.21円で換算しております。
Back to Top
トゥレット症候群治療薬の世界市場:2019年~2023年 Tourette's Syndrome Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023
出版日: 2019年09月03日 ページ情報: 英文 145 Pages
概要

世界のトゥレット症候群治療薬市場は、トゥレット症候群に対する認識の高まり、規制上のインセンティブ、疾患の病的性質などが成長促進要因となり、予測期間中に約5%のCAGRで拡大する見込みです。ただし、非薬物療法の採用、診断の難しさ、および後期臨床試験での薬剤などの要因が、予測期間にわたってトゥレット症候群治療薬産業の成長を妨げる可能性があります。

当レポートでは、世界のトゥレット症候群治療薬市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • 抗精神病薬
  • 非抗精神病薬
  • 市場機会:製品別

第7章 顧客情勢

第8章 地域別景観

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • 新規治療薬の開発
  • 戦略的提携の増加
  • トゥレット症候群の遺伝的真因を理解するための調査研究の増加

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • H. Lundbeck AS
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • 大塚ホールディングス
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR31983

About this market

Technavio's Tourette's syndrome drugs market analysis considers sales from both antipsychotics and non-antipsychotics products. Our analysis also considers the sales of Tourette's syndrome drugs in Asia, Europe, North America, and ROW. In 2018, the antipsychotics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the strong therapeutic value of antipsychotics will play a significant role in the antipsychotics segment to maintain its market position. Also, our global Tourette's syndrome drugs market report looks at factors such as growing awareness about Tourette's syndrome, regulatory incentives, and its morbid nature of disease. However, adoption of non-pharmacological therapies, difficulty in diagnosis, and drug in late-stage clinical trials may hamper the growth of the Tourette's syndrome drugs industry over the forecast period.

Overview

Morbid nature of the disease

As Tourette's syndrome is basically a neurodevelopment syndrome that produces results in repetitive, involuntary movements and unwanted sounds - collectively termed as tics - it . This syndrome is often accompanied by other syndromes disorders such as attention deficit hyperactivity disorder ADHD and obsessive-compulsive disorderOCD. This can result in ese condition leads to poor psychological functioning and quality of life. Therefore, a supportive environmental, behavioral and emotional support is necessary to overcome the challenges faced by the patients. Several non-antipsychotic and atypical antipsychotic drugs, such as quetiapine, olanzapine, risperidone, and aripiprazole are available at low cost that helps in suppressing tics in patients with Tourette's syndrome. This low cost and morbid nature of disease will lead to the expansion of the global Tourette's syndrome drugs market at a CAGR of almost 5% during the forecast period.

Development of novel therapeutics

Several pharmaceutical companies and researchers are focusing on the development of novel drugs that correct the dopaminergic disturbances responsible for motor and vocal tics in Tourette's syndrome patients. For instance, ecopipam, a first-in-class drug developed by Emalex Biosciences, selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor pediatric patients. Also, Therapix Biosciences is evaluating the efficacy and safety of THX-110, a drug candidate platform for the treatment of symptoms related to Tourette's syndrome. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global Tourette's syndrome drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global Tourette's syndrome drugs market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position. , and in In line with this, this report provides a detailed analysis of several leading Tourette's syndrome drugs manufacturers, that include AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., H. Lundbeck AS, Johnson & Johnson Services Inc., Mylan NV, Otsuka Holdings Co. Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.

Also, the Tourette's syndrome drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Antipsychotics - Market size and forecast 2018-2023
  • Non-antipsychotics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Development of novel therapeutics
  • Increasing strategic alliances
  • Growing number of research studies to understand genetic root cause of
  • Tourette's syndrome

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • H. Lundbeck AS
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Antipsychotics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Antipsychotics - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Non-antipsychotics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Non-antipsychotics - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: AstraZeneca Plc - Vendor overview
  • Exhibit 49: AstraZeneca Plc - Business segments
  • Exhibit 50: AstraZeneca Plc - Organizational developments
  • Exhibit 51: AstraZeneca Plc - Geographic focus
  • Exhibit 52: AstraZeneca Plc - Key offerings
  • Exhibit 53: AstraZeneca Plc - Key customers
  • Exhibit 54: Boehringer Ingelheim International GmbH - Vendor overview
  • Exhibit 55: Boehringer Ingelheim International GmbH - Business segments
  • Exhibit 56: Boehringer Ingelheim International GmbH - Organizational developments
  • Exhibit 57: Boehringer Ingelheim International GmbH - Geographic focus
  • Exhibit 58: Boehringer Ingelheim International GmbH - Segment focus
  • Exhibit 59: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 60: Boehringer Ingelheim International GmbH - Key customers
  • Exhibit 61: Eli Lilly and Co. - Vendor overview
  • Exhibit 62: Eli Lilly and Co. - Business segments
  • Exhibit 63: Eli Lilly and Co. - Organizational developments
  • Exhibit 64: Eli Lilly and Co. - Geographic focus
  • Exhibit 65: Eli Lilly and Co. - Segment focus
  • Exhibit 66: Eli Lilly and Co. - Key offerings
  • Exhibit 67: Eli Lilly and Co. - Key customers
  • Exhibit 68: H. Lundbeck AS - Vendor overview
  • Exhibit 69: H. Lundbeck AS - Business segments
  • Exhibit 70: H. Lundbeck AS - Organizational developments
  • Exhibit 71: H. Lundbeck AS - Geographic focus
  • Exhibit 72: H. Lundbeck AS - Key offerings
  • Exhibit 73: H. Lundbeck AS - Key customers
  • Exhibit 74: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 75: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 76: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 77: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 78: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 79: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 80: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 81: Mylan NV - Vendor overview
  • Exhibit 82: Mylan NV - Product segments
  • Exhibit 83: Mylan NV - Organizational developments
  • Exhibit 84: Mylan NV - Geographic focus
  • Exhibit 85: Mylan NV - Segment focus
  • Exhibit 86: Mylan NV - Key offerings
  • Exhibit 87: Mylan NV - Key customers
  • Exhibit 88: Otsuka Holdings Co. Ltd. - Vendor overview
  • Exhibit 89: Otsuka Holdings Co. Ltd. - Business segments
  • Exhibit 90: Otsuka Holdings Co. Ltd. - Organizational developments
  • Exhibit 91: Otsuka Holdings Co. Ltd. - Geographic focus
  • Exhibit 92: Otsuka Holdings Co. Ltd. - Segment focus
  • Exhibit 93: Otsuka Holdings Co. Ltd. - Key offerings
  • Exhibit 94: Otsuka Holdings Co. Ltd. - Key customers
  • Exhibit 95: Pfizer Inc. - Vendor overview
  • Exhibit 96: Pfizer Inc. - Business segments
  • Exhibit 97: Pfizer Inc. - Organizational developments
  • Exhibit 98: Pfizer Inc. - Geographic focus
  • Exhibit 99: Pfizer Inc. - Segment focus
  • Exhibit 100: Pfizer Inc. - Key offerings
  • Exhibit 101: Pfizer Inc. - Key customers
  • Exhibit 102: Sun Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 103: Sun Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 104: Sun Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 105: Sun Pharmaceutical Industries Ltd. - Geographic focus
  • Exhibit 106: Sun Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 108: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 109: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 110: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 111: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 112: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 114: Validation techniques employed for market sizing
  • Exhibit 115: Definition of market positioning of vendors
Back to Top